270 related articles for article (PubMed ID: 18069393)
1. [Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
Zarebska-Michaluk D; Lebensztejn DM; Kryczka W
Przegl Epidemiol; 2007; 61(3):551-8. PubMed ID: 18069393
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
Juszczyk J; Bolewska B; Flieger J; Swietek K; Adamek B; Biskupska-Karasińska M; Dziambor AP; Boroń-Kaczmarska A; Wawrzynowicz-Syczewska M; Cianciara J; Kozłowska J; Daniluk J; Słomka M; Dudziak M; Zaborowski P; Gładysz A; Piszko P; Gonciarz Z; Mazur W; Machniak M; Kryczka W; Zarebska-Michaluk D; Trocha H; Witczak-Malinowska K; Lakomy E; Kuydowicz J; Niwicka-Michałowska A
Pol Merkur Lekarski; 2001 Oct; 11(64):340-3. PubMed ID: 11770315
[TBL] [Abstract][Full Text] [Related]
3. [The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
Sulka A; Simon K; Jeleń M; Piszko P
Przegl Epidemiol; 2005; 59(2):455-66. PubMed ID: 16190554
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists].
Hofmann WP; Bock H; Weber C; Tacke W; Pfaff R; Kihn R; Moog G; Kellner HU; Schöfer M; Frick B; Berg P; Rambow A; Friedrich-Rust M; Herrmann E; Sarrazin C; Zeuzem S
Z Gastroenterol; 2006 Jan; 44(1):25-31. PubMed ID: 16397836
[TBL] [Abstract][Full Text] [Related]
5. [Retreatment of patients with chronic hepatitis C].
Ostojić R
Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
[TBL] [Abstract][Full Text] [Related]
6. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
[TBL] [Abstract][Full Text] [Related]
7. 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
van Leeuwen DJ; Yee LJ; Langner RG
Am J Gastroenterol; 2002 Feb; 97(2):497-8. PubMed ID: 11866304
[No Abstract] [Full Text] [Related]
8. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
[TBL] [Abstract][Full Text] [Related]
9. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
[No Abstract] [Full Text] [Related]
10. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
11. Interferon plus ribavirin: a cautionary note.
Macedo G; Ribeiro T
Am J Gastroenterol; 1999 Oct; 94(10):3087-8. PubMed ID: 10520894
[No Abstract] [Full Text] [Related]
12. Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus.
Iino S
Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):216-7. PubMed ID: 10379483
[No Abstract] [Full Text] [Related]
13. Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
Predescu O; Streba LA; Irimia E; Streba L; Mogoantă L
Rom J Morphol Embryol; 2012; 53(3):497-502. PubMed ID: 23010773
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with natural interferon (alfaferone) in clinical practice--our experience].
Dybowska D; Halota W
Przegl Epidemiol; 2007; 61(1):17-22. PubMed ID: 17702434
[TBL] [Abstract][Full Text] [Related]
15. [Chronic hepatitis C--therapeutic modalities for interferon failure].
Hermann R
Praxis (Bern 1994); 1998 Oct; 87(42):1413-20. PubMed ID: 9824949
[TBL] [Abstract][Full Text] [Related]
16. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
[TBL] [Abstract][Full Text] [Related]
17. [New strategies for treatment of chronic hepatitis C].
Rizzetto M
Forum (Genova); 1999; 9(2 Suppl):1-11. PubMed ID: 11300125
[No Abstract] [Full Text] [Related]
18. [Treatment of chronic viral hepatitis].
Pedersen C; Pedersen CR
Ugeskr Laeger; 2008 Jun; 170(24):2137-40. PubMed ID: 18565297
[TBL] [Abstract][Full Text] [Related]
19. [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
Larrey D
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B283-90. PubMed ID: 12180302
[No Abstract] [Full Text] [Related]
20. [Therapeutic progresses of hepatitis C].
Ma QY
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):501-2. PubMed ID: 12939190
[No Abstract] [Full Text] [Related]
[Next] [New Search]
